Radiomics Analysis of 177Lu-PSMA I&T Radioligand Therapy Dosimetry in a Castration Resistant Metastatic Prostate Cancer Patient

177Lu-DOTAGA-(l-y)fk(Sub-KuE) (177Lu-PSMA I amp;T) is currently used for radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) in several centers in Europe. It was launched in Tallinn, Estonia, in December 2018. As an additional project, a model of dosimetric analysis was created, utilizing voxel-based dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry [1]. This was a successful project, and the work is summarized in this chapter.